Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vectorite Biomedical's Enterprise Value is NT$377.28 Mil.
Vectorite Biomedical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-9.78 Mil. Therefore, Vectorite Biomedical's EV-to-FCF for today is -38.57.
The historical rank and industry rank for Vectorite Biomedical's EV-to-FCF or its related term are showing as below:
ROCO:4170'
s EV-to-FCF Range Over the Past 10 Years
Min: -189.37 Med: -8.37 Max: 94.74
Current: -38.12
During the past 13 years, the highest EV-to-FCF of Vectorite Biomedical was 94.74. The lowest was -189.37. And the median was -8.37.
ROCO:4170's EV-to-FCF is ranked worse than 100% of 335
companies
in the Biotechnology industry
Industry Median: 15.34
vs ROCO:4170: -38.12
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vectorite Biomedical's PE Ratio (TTM) for today is calculated as:
Vectorite Biomedical's share price for today is NT$12.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectorite Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$2.190.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vectorite Biomedical EV-to-FCF Related Terms
Vectorite Biomedical EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Vectorite Biomedical's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4170 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Vectorite Biomedical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vectorite Biomedical EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vectorite Biomedical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vectorite Biomedical's EV-to-FCF falls into.
Vectorite Biomedical's current Enterprise Value is NT$377.28 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vectorite Biomedical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-9.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vectorite Biomedical (ROCO:4170) has a EV-to-FCF of -38.57 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vectorite Biomedical and its competitors. According to the industry distribution chart, Vectorite Biomedical ranks #999999 out of 335 companies in the Biotechnology industry.
Is Vectorite Biomedical's EV-to-FCF too high?
Vectorite Biomedical's current EV-to-FCF is -38.57. Based on the distribution chart, Vectorite Biomedical ranks #999999 out of 335 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Vectorite Biomedical has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vectorite Biomedical's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vectorite Biomedical ranks #999999 out of 335 companies for EV-to-FCF. This places Vectorite Biomedical in the lower half of its industry. The industry median EV-to-FCF is 15.34. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.34, based on 335 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vectorite Biomedical and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vectorite Biomedical's current EV-to-FCF is -38.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectorite Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Vectorite Biomedical (ROCO:4170) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$17.56, compared to a current price of NT$12.50 — trading 28.8% below its estimated fair value. The current EV-to-FCF is -38.57. Vectorite Biomedical's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vectorite Biomedical (ROCO:4170), the current EV-to-FCF is -38.57 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vectorite Biomedical (ROCO:4170) Overvalued in 2026?
Based on GuruFocus' analysis, Vectorite Biomedical stock appears to be undervalued.
The current stock price of NT$12.50 is trading 28.8% below its estimated GF Value™ of NT$17.56.
GuruFocus considers Vectorite Biomedical to be Modestly Undervalued.
Key valuation signals for ROCO:4170:
EV-to-FCF: -38.57
GF Value™: NT$17.56 vs. price of NT$12.50 (28.8% below fair value)
No single metric tells the full story. See the ROCO:4170 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vectorite Biomedical Inc is a Taiwan-based biotechnology research and development, cell product (preparation) manufacturing and immune cell collection and storage business.
65GF Score
Get the complete analysis for ROCO:4170
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4170 has been successfully added to your 
